Table 1.
HCC (n = 20) | mCRC (n = 22) | |
---|---|---|
Sex | 92% men | 75% men |
Age | 65 ± 12 | 58 ± 11 |
Tumor histology | 56% well differentiated, 35% moderately differentiated, 9% undifferentiated | 82% adenocarcinoma, 18% colloid adenocarcinoma |
Tumor size (cm) | 4 ± 3 | 2 ± 1 |
Liver metastases | 1–5 | |
Associated hepatic pathologies (SA successful amplification) | Alcoholic cirrhosis (n = 8; 4 SA) Hemochromatosis (n = 5; 4 SA) | |
Previous chemotherapy | Chemoembolization (n = 2; 0 SA) Epirubicin/cisplatin/5FU (n = 1; 1 SA) |
Folfox (n = 4; 3SA) Folfiri (n = 4; 1 SA) 5-FU (n = 1; 1 SA) |